ARTICLE | Clinical News
China FDA approves IND for Canbridge's GBM candidate
April 13, 2018 3:18 PM UTC
Canbridge Life Sciences Ltd. (Beijing, China) said China FDA approved an IND to begin a Phase II/III trial of asunercept (APG101, CAN-008) to treat glioblastoma multiforme (GBM).
A spokesperson told BioCentury that Canbridge plans to dose the first patient in the trial later this year...
BCIQ Target Profiles